Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, Mfr. by: Towa Pharmac...

FDA Recall #D-0009-2025 — Class II — October 10, 2024

Recall #D-0009-2025 Date: October 10, 2024 Classification: Class II Status: Completed

Product Description

Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Distributed by: BPI, NDC 51991-746-05.

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Recalling Firm

Breckenridge Pharmaceutical, Inc — Berlin, CT

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

7,107 bottles

Distribution

Product was distributed nationwide within the United States

Code Information

Lot #: 220128, Exp. Date 12/2024

Status

Completed

Voluntary / Mandated

Voluntary: Firm initiated